Saturday 17 October 2026
Export IMRX’s income statement to Excel — free account
Immuneering Corporation
IMRX Healthcare Biotechnology
Immuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00. In the quarter to June 2026, EPS grew 32.5% and free cash flow fell 74.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.59
0.05
−1.37%
Follow IMRX
Immuneering Corporation (IMRX) P/E ratio
Immuneering Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| FATE Fate Therapeutics, Inc. compare | n/m |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| ACIU AC Immune compare | n/m |
| SABS SAB Biotherapeutics, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| IMRX Immuneering Corporation | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| QTTB Q32 Bio Inc. compare | 2.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)